Cyclophosphamide 'Pulses' in Chronic Progressive Multiple Sclerosis
- 1 August 1987
- journal article
- research article
- Published by American Medical Association (AMA) in Archives of Neurology
- Vol. 44 (8) , 828-832
- https://doi.org/10.1001/archneur.1987.00520200032014
Abstract
• To our knowledge, this is the first clinical trial in multiple sclerosis (MS) demonstrating the feasibility of directing immunomodulating therapy by monitoring immunologic results. Cyclophosphamide was administered at monthly intervals, escalating the dose until there was a significant reduction in both the number of blood B lymphocytes and helper/inducer (CD4) T cells of 14 patients with chronic progressive MS. The frequency and severity of adverse effects led us to conclude that the regimen is too toxic for the long-term treatment of patients with MS.This publication has 25 references indexed in Scilit:
- The effect of cyclophosphamide on the immune system: implications for clinical cancer therapyCancer Chemotherapy and Pharmacology, 2016
- The immunopharmacology of cyclophosphamidePublished by Elsevier ,2002
- T-cell subpopulations in blood and cerebrospinal fluid of multiple sclerosis patients: Effect of cyclophosphamideClinical Immunology and Immunopathology, 1983
- Age dependent differential effects of cyclophosphamide on natural antibody levels in chickensDevelopmental & Comparative Immunology, 1982
- Intensive immunosuppression with cyclophosphamide in multiple sclerosisZeitschrift für Neurologie, 1977
- Treatment of the chronic progressive form of multiple sclerosis with a combination of cyclophosphamide and prednisoneClinical Neurology and Neurosurgery, 1975
- Urinary-Bladder Fibrosis and Telangiectasia Associated with Long-Term Cyclophosphamide TherapyNew England Journal of Medicine, 1971
- CYCLOPHOSPHAMIDE IN MULTIPLE SCLEROSISThe Lancet, 1969
- On the evaluation of disability in multiple sclerosisNeurology, 1961
- A New Scale for Evaluating Disability in Multiple SclerosisNeurology, 1955